Prothena (PRTA)
(Delayed Data from NSDQ)
$17.22 USD
+0.44 (2.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $17.22 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
PRTA 17.22 +0.44(2.62%)
Will PRTA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PRTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRTA
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
What Makes Prothena (PRTA) a New Buy Stock
PRTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for PRTA
EcoR1 Capital, LLC Increases Stake in Galapagos NV
Biotech Alert: Searches spiking for these stocks today
Breaking Down Prothena Corp: 4 Analysts Share Their Views
Prothena price target lowered by $2 at BofA, here's why
Prothena Buy Rating Affirmed: Leadership Changes and Prasinezumab’s Promise Signal Investment Opportunity